Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MDT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MDT and 80,000+ other tickers.
See exactly how MDT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDT and 80,000+ other tickers.
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It…
MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.
Factors such as the prospect of slow dividend growth could make Medtronic stock less attractive to income-focused investors. For investors interested in both income and capital growth, much suggests that Medtronic remains a strong choice to buy and hold over the next few years.
Medtronic is one of the world's largest medical device companies. Medtronic has reshaped its business, with a focus on returning to growth.
California State Teachers Retirement System increased its holdings in Medtronic PLC (NYSE: MDT) by 7,655.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 158,124,578 shares of the medical technology company's stock after buying an additional 156,085,748 shares during the
Medtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.